Antibody based conditioning for allogeneic hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is vital for treating blood disorders but relies on harsh preconditioning.
• Conventional methods cause significant tissue injury and graft-versus-host disease (GVHD).
• Targeted radiotherapy and novel antibody-based strategies aim to improve allo-HSCT efficacy and safety.

Purpose of the Study:

• To review antibody-based conditioning strategies for allo-HSCT.
• To discuss the use of native antibodies, radioimmunoconjugates (ROICs), and antibody-drug conjugates (ADCs).
• To highlight advancements in selective targeting of hematopoietic and immune cells.

Main Methods:

• Review of existing literature on antibody-based conditioning for allo-HSCT.
• Analysis of preclinical data for ROICs and ADCs in mouse models.
• Examination of strategies involving nonmyeloablative preconditioning and co-stimulatory blockade.

Main Results:

• ROICs show clinical benefits by reducing relapse without increasing mortality through targeted radiation.
• Preclinical models demonstrate successful mixed chimerism and tolerance with nonmyeloablative conditioning and antibody blockade.
• Antibody-drug conjugates show promise as monotherapy or with reduced intensity conditioning in preclinical studies.

Conclusions:

• Antibody-based conditioning offers a less toxic alternative to conventional allo-HSCT preconditioning.
• Targeted approaches like ADCs have the potential to improve engraftment and reduce adverse effects.
• Further research into antibody-mediated strategies is crucial for advancing allo-HSCT.